Kodiak Sciences

Biotechnology ResearchCalifornia, United States51-200 Employees

Kodiak Sciences is a biotechnology research company focused on developing therapies for high-prevalence retinal diseases. Its discovery approach centers on the ABC Platform, which blends antibody-based and chemistry-based strategies to advance next-generation retinal medicines. The company lists tarcocimab as its lead investigational medicine, with KSI-501 and KSI-101 as additional candidates targeting retinal vascular and inflammatory conditions. 

Kodiak's target customers are patients suffering from retinal vascular and inflammatory diseases, with solutions aimed at improving durability and addressing biology beyond VEGF. It is based in Palo Alto, California, within the Silicon Valley biotech ecosystem, and is described as a mid-sized enterprise. A recent development notes that the chief executive officer is scheduled to present at a major healthcare conference in New York in June 2026.

Sign up for free to view info

Email Format Employee directory